| Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patients.CNS Spectr | PMID 36226902无 PMCID | 2023-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of physical activity on postural stability and coordination in children with posterior fossa tumor: randomized control phase III trial.J Cancer Res Clin Oncol | PMID 36525069PMC10356666 | 2023-Aug | 0.90 | Eligible trial type (randomized, phase III, oncology, human) but the reported outcomes are functional/quality-of-life measures, not the required survival or tumor-related efficacy outcomes. | 待处理 |
| Bevacizumab biosimilar candidate TAB008 compared to Avastin® in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study.J Cancer Res Clin Oncol | PMID 36595042PMC11796671 | 2023-Aug | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Efficacy and safety of 1.5% levofloxacin otic solution for the treatment of otitis media in a multicenter, randomized, double-blind, parallel-group, placebo-controlled, phase III study.Auris Nasus Larynx | PMID 36599786无 PMCID | 2023-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial.J Cancer Res Clin Oncol | PMID 36680581PMC9864499 | 2023-Aug | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: The Randomized Phase 3 MOJAVE Study.Am J Ophthalmol | PMID 36948372无 PMCID | 2023-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Construct validity and responsiveness of a health-related symptom index for persons either treated or monitored for anal high-grade squamous intraepithelial lesions (HSIL): AMC-A01/-A03.Qual Life Res | PMID 37020153PMC10330891 | 2023-Aug | 0.90 | The record is a methodological study of a patient-reported outcome instrument developed for a Phase III trial, not a report of the trial's efficacy results. It lacks a drug intervention and a time-to-event efficacy endpoint. | 待处理 |
| Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy.Transplant Cell Ther | PMID 37120136无 PMCID | 2023-Aug | 0.95 | The record is a Phase III randomized trial of a drug-containing intervention (omidubicel) in an oncology setting, but the specific report is a secondary substudy analyzing immune reconstitution and viral infection rates, not reporting a primary time-to-event efficacy endpoint (e.g., OS, PFS) or Kaplan-Meier/HR results for such an endpoint. Therefore, it does not meet the inclusion criteria for a primary or key secondary efficacy endpoint analysis. | 待处理 |
| A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High-Risk Retroperitoneal Sarcoma (STRASS2).Ann Surg Oncol | PMID 37170037PMC10687743 | 2023-Aug | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.Eur Urol | PMID 37179241PMC10662642 | 2023-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.Cancer Sci | PMID 37183528PMC10394135 | 2023-Aug | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial.Urol Oncol | PMID 37198025无 PMCID | 2023-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Radiotherapy for Ledderhose disease: Results of the LedRad-study, a prospective multicentre randomised double-blind phase 3 trial.Radiother Oncol | PMID 37211283无 PMCID | 2023-Aug | 0.90 | The study is a randomized phase III trial with original results, but it is excluded because it is not oncology (it treats non-malignant Ledderhose disease) and does not involve a drug-containing intervention or a time-to-event efficacy endpoint. | 待处理 |
| Long-term effectiveness of a novel intra-oral electro-stimulator for the treatment of dry mouth in patients with Sjogren's syndrome: A randomised sham-controlled feasibility study (LEONIDAS-1).J Oral Pathol Med | PMID 37220073PMC10946757 | 2023-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.Amyotroph Lateral Scler Frontotemporal Degener | PMID 37254449无 PMCID | 2023-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.Gynecol Oncol | PMID 37262961无 PMCID | 2023-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.Eur J Cancer | PMID 37263896无 PMCID | 2023-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Development and evaluation of DiabeText, a personalized mHealth intervention to support medication adherence and lifestyle change behaviour in patients with type 2 diabetes in Spain: A mixed-methods phase II pragmatic randomized controlled clinical trial.Int J Med Inform | PMID 37267809无 PMCID | 2023-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.Ann Oncol | PMID 37268157无 PMCID | 2023-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.Eur J Cancer | PMID 37277264无 PMCID | 2023-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study.Cancer Med | PMID 37325938PMC10469638 | 2023-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients.Clin Breast Cancer | PMID 37336651无 PMCID | 2023-Aug | 0.90 | The record describes a phase III randomized trial in oncology with drug intervention, but the analysis presented is a secondary/biomarker analysis focusing on the association between obesity and circulating tumor cells. The endpoint is CTC positivity (a binary/prognostic factor), not a time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the required time-to-event efficacy endpoint criterion for inclusion in the KM cohort. | 待处理 |
| A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP.Br J Haematol | PMID 37339869无 PMCID | 2023-Aug | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.Lancet Haematol | PMID 37385272PMC10528809 | 2023-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.ESMO Open | PMID 37390764PMC10485403 | 2023-Aug | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.Cancer Commun (Lond) | PMID 37403255PMC10397561 | 2023-Aug | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.Lancet Haematol | PMID 37414062无 PMCID | 2023-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.Lancet Oncol | PMID 37423227无 PMCID | 2023-Aug | 0.85 | The trial is a phase 3 randomized controlled trial in human oncology with original results. However, it is not eligible because it does not have a drug-containing intervention (the intervention is a radiotherapy technique, DO-IMRT vs standard IMRT) and its primary endpoint is a patient-reported quality-of-life measure (MDADI score), not a time-to-event efficacy endpoint like OS, PFS, or DFS. | 待处理 |
| Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.Lancet HIV | PMID 37451297无 PMCID | 2023-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial.J Neurooncol | PMID 37452916无 PMCID | 2023-Aug | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.Nat Med | PMID 37524953PMC10427418 | 2023-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| [First-line maintenance therapy of adult patients with BCG-naïve high-risk non-muscle-invasive bladder cancer - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) - SunRISe-3 - AB 85/23 of AUO].Aktuelle Urol | PMID 37541235无 PMCID | 2023-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens.ESMO Open | PMID 37542912PMC10485393 | 2023-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Factors Associated With Altmetric Attention Scores for Randomized Phase III Cancer Clinical Trials.JCO Clin Cancer Inform | PMID 37552823无 PMCID | 2023-Aug | 0.90 | The study is a bibliometric analysis of Phase III cancer RCTs, not a report of clinical outcomes from such a trial. | 待处理 |
| Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis.RMD Open | PMID 37604638PMC10445377 | 2023-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments.RMD Open | PMID 37652554PMC10476119 | 2023-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A multicenter randomized, controlled clinical trial of adjuvant sintilimab for esophageal squamous cell carcinoma.Future Oncol | PMID 37737025无 PMCID | 2023-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.Lancet Rheumatol | PMID 38251577无 PMCID | 2023-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Updates of perioperative multidisciplinary treatment for surgically resectable esophageal cancer.Jpn J Clin Oncol | PMID 37282626无 PMCID | 2023-Jul-31 | 0.45 | The record is a review article summarizing multiple trials, not an original result report of a single randomized trial. It lacks primary time-to-event efficacy data (e.g., KM curves, HR) for any specific trial, which is required for eligibility. | 待处理 |
| Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A phase III study (V114-033).Vaccine | PMID 37344262无 PMCID | 2023-Jul-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.Lancet | PMID 37311468无 PMCID | 2023-Jul-29 | 0.85 | The trial is an oncology Phase 3 randomized study with a drug intervention and original results, but the primary efficacy endpoint is a categorical response (transfusion independence with Hb increase), not a time-to-event endpoint. Therefore, it does not meet the time-to-event requirement for inclusion. | 待处理 |
| Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.N Engl J Med | PMID 37272512无 PMCID | 2023-Jul-27 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.N Engl J Med | PMID 37356066无 PMCID | 2023-Jul-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| [Comparison of the effects and safety of dydrogesterone and medroxyprogesterone acetate on endometrial hyperplasia without atypia: a randomized controlled non-inferior phase Ⅲ clinical study].Zhonghua Fu Chan Ke Za Zhi | PMID 37474326无 PMCID | 2023-Jul-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.Lancet | PMID 37285865无 PMCID | 2023-Jul-22 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.N Engl J Med | PMID 37272521无 PMCID | 2023-Jul-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.Neurology | PMID 37268435PMC10382259 | 2023-Jul-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial.JAMA | PMID 37354562PMC10354685 | 2023-Jul-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of the FAKHRAVAC compared with BBIBP-Corv2 against SARS-CoV-2 in adults: a non-inferiority multi-center trial.Virol J | PMID 37464440PMC10355035 | 2023-Jul-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.Cancer | PMID 37151113无 PMCID | 2023-Jul-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |